Microregional effects of gemcitabine in HCT-116 xenografts

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6537-6541

  Huxham, Lynsey A ^a   Kyle, Alastair H ^a   Baker, Jennifer H E ^a   Nykilchuk, Lani K ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CARBOCYANINE; CD31 ANTIGEN; GEMCITABINE; PIMONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; CELL CYCLE S PHASE; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; GENE MAPPING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644279732     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0986     Document Type: Article

References (22)

1. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
2. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
3. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
4. Kyle AH, Huxham LA, Baker JHE, Burston HE, Minchinton AI. Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res 2003;63:5707-11.
5. Hertel LW, Kroin JS, Misner JE. Synthesis of 2-deoxy-2′,2′- difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988;53:2406-9.
6. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabino-furanosylcytosine. Cancer Res 1988;48:4024-31.
7. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-22.
8. Mackey JR, Mani RS, Selner M, et al, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res 1998;58:4349-57.
9. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ, Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000;60:6075-9.
10. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(Suppl 11):3-10.
11. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72.
12. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(Suppl 10):3-15.
13. Wexler EJ, Gravallese EM, Czerniak PM, et al. Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments. Clin Cancer Res 2000;6:3361-70.
14. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
15. Cappella P, Tomasoni D, Faretta M, et al. Cell cycle effects of gemcitabine. Int J Cancer 2001;93:401-8.
16. Cowan DSM, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer 1996;74:S28-31.
17. Kyle AH, Chan CT, Minchinton AI. Characterisation of three dimensional tissue cultures using electrical impedance spectroscopy. Biophys J 1999;76.
18. Minchinton AI, Wendt KR, Clow KA, Fryer KH. Multilayers of cells growing on a permeable support: an in vitro tumour model. Acta Oncol 1997;36:13-6.
19. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240:177-84.
20. Veerman G, Ruiz van Haperen VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′- difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-42.
21. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 1410-1.
22. Cividalli A, Mauro F, Livdi E, et al. Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma. J Cancer Res Clin Oncol 2000;126:461-7.